pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Jul 14·1 min read
save

BIO 2026 in San Diego features executive interviews on biotech trends and opportunities

Jul 14, 2026·read at Fierce Biotech ↗Neutral

The BIO International Convention gathered more than 20,000 life‑science leaders in San Diego, serving as a major forum for biotech discussion.

During the event, Fierce conducted a series of video interviews with industry executives, exploring current trends, innovations and investment opportunities shaping the sector.

The interviews are available online, offering insights into challenges and breakthroughs that could influence the future of healthcare. The editorial staff did not create the content.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “BIO San Diego 2026 Executive Interviews”

read at Fierce Biotech ↗
133 words · retrieved Jul 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5h agoPfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ dealFierce Biotech
  • 8h agoAbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialFierce Biotech
  • 12h agoGSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetFierce Biotech
  • 14h agoUltragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’Fierce Biotech
  • 1d agoFortrea boosts early-phase CRO platform with $45M acquisition of Worldwide divisionFierce Biotech